Industry News

Sandoz Recalls 2nd Lot of Cefazolin Because of Mispackaging

A second lot of cefazolin was recalled due to mislabeling.

JULY 2, 2025

Sanofi Accelerates Beyfortus Shipping Ahead of Next RSV Season

Sanofi said it would ship nirsevimab starting earlier to ensure broad availability well ahead of the 2025-2026 RSV season.

JUNE 9, 2025

New Test Launches to Detect Respiratory Pathogens in Wastewater

A new option will be available soon to test wastewater for potential infectious respiratory disease outbreaks.

APRIL 22, 2025

Endotoxin Assay Moves From the Beach to the Bench

“Save the horseshoe crab!” may not stir the same public fervor as campaigns to preserve other more popular animal species whose survival is imperiled. But for those dedicated to the quality and safety of injectable medicines, vaccines and medical devices—and for the millions of people who rely on their work—the prospect of horseshoe crab populations diminishing is an existential concern.

FEBRUARY 12, 2025

FDA Accepts BLA for Clesrovimab to Protect Infants From RSV Disease

The FDA accepted the biologics license application for clesrovimab (MK-1654), Merck’s investigational, prophylactic, long-acting monoclonal antibody designed to protect infants from RSV.

JANUARY 13, 2025

FDA Grants Breakthrough Device Designation to New Sepsis Test

The FDA has granted Breakthrough Device designation to a new rapid diagnostic blood test for sepsis (MeMed Severity, MeMed).

DECEMBER 10, 2024

Conserving IV Fluids Critical as Hurricane Flooding Damages Key Facility

One of the issues to deal with in the aftermath of Hurricane Helene is the possible shortage of IV fluids; no telling yet what Milton may do to the supply chain.

OCTOBER 9, 2024

Atovaquone Oral Suspension Recalled Due to Bacterial Contamination

Atovaquone is a quinone antimicrobial drug indicated to prevent Pneumocystis jirovecii pneumonia. A single batch was contaminated with bacteria.

SEPTEMBER 20, 2024

Karius Secures BARDA Contract to Expand Detection of Pathogens

Karius received a contract from the Division of Research, Innovation, and Ventures (DRIVe), under the BARDA, valued at more than $600,000, that enables Karius to extend its current DNA pathogen detection capabilities to include RNA pathogen detection.

AUGUST 12, 2024